Adagene Announces FDA Fast Track Designation for Muzastotug (ADG126)
Adagene Announces FDA Fast Track Designation for Muzastotug (ADG126) GlobeNewswire December 16, 2025 Designation underscores the potential of SAFEbody(R)-enabled anti-CTLA-4 therapy to address unmet need in MSS colorectal cancer SAN DIEGO and SUZHOU, China, Dec. 16, 2025 (GLOBE NEWSWIRE) — Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based […]